

# REACH Data requirements & Evaluation

Visit of the delegation from Brazilian  
Ministry of Environment and  
Institute of Environment and Renewable  
Natural Resources to ECHA

15 April 2013

Dr Derek J Knight  
Senior Scientific Advisor



## REACH & CLP: information on chemicals & addressing chemicals of concern



- Pre-registration
- Data sharing
- Registration
- Self-Classification

**Industry gathers information and ensures responsible and well-informed management of the risks**



- **Evaluation**
  - Dossier evaluation
  - Substance evaluation

**ECHA and MSCAs control and request for further info**



- Authorisation
- Restriction
- Harmonised C&L

**COM, with support of ECHA and MSCAs, applies community wide risk management measures**

## REACH: Registration




- **Core of REACH:** EU/EEA manufacturers and importers of chemicals collectively obtain information per substance and use knowledge to ensure safe use
- Registration:
  - IUCLID format technical dossier for substances at 1 t.p.a. submitted using REACH-IT
  - Standard **information linked to tonnage**
  - **Testing Proposals for higher-tier studies** (i.e. at 100 & 1,000 t.p.a.)
  - **Chemical Safety Report** for substances at 10 t.p.a.
  - Transitional arrangements, i.e. **'phase in' substances registered in 3 stages**

## Properties of Chemical Substances

- To define and characterise the substance.
- To identify the hazardous properties for hazard communication.
- To identify and quantify the hazardous properties for risk assessment.
- To obtain parameters necessary for exposure assessment models for risk assessment.
- Physico-chemical, toxicology & environmental (ecotoxicity & environmental fate)

## Standard core registration data

Annex	Human Health	Environment
<b>Annex VII</b> (≥ 1 t.p.a.)  <b>Plus physico-chemical tests</b>	<ul style="list-style-type: none"> <li>• <b><i>In vitro</i> skin and eye irritation</b></li> <li>• <b>Skin sensitisation</b></li> <li>• <b><i>In vitro</i> mutagenicity</b></li> <li>• <b>Acute toxicity (one route)</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Short term toxicity (daphnia, algae)</b></li> <li>• <b>Degradation (biotic)</b></li> </ul>
<b>Annex VIII</b> (≥ 10 t.p.a.)	<ul style="list-style-type: none"> <li>• <b><i>In vivo</i> skin and eye irritation</b></li> <li>• <b>Further <i>in vitro</i> mutagenicity</b></li> <li>• <b>Acute toxicity (2nd route)</b></li> <li>• <b>Short-term RdT (28 days)</b></li> <li>• <b>Reproductive toxicity screening</b></li> <li>• <b>Assessment of toxicokinetics</b> (not a testing requirement)</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Short term toxicity (fish)</b></li> <li>• <b>Respiration inhibition test</b></li> <li>• <b>Degradation (hydrolysis)</b></li> <li>• <b>Fate (absorption/desorption)</b></li> </ul>



**Increased use of animals and/or costs**

# Higher-tier data for Testing Proposals

Annex	Human Health	Environment
Annex IX (≥ 100 t.p.a.)	<ul style="list-style-type: none"> <li>• Further <i>in vivo</i> mutagenicity studies (if + results)</li> <li>• Sub-chronic toxicity (90-days)</li> <li>• Reproductive toxicity tests</li> </ul>	<ul style="list-style-type: none"> <li>• Long-term toxicity (invertebrates, fish)</li> <li>• Biotic degradation (simulation studies)</li> <li>• Identification of degradation products</li> <li>• Fate: bioaccumulation in fish, further absorption/desorption</li> <li>• Short term toxicity- terrestrial organisms (invertebrates, micro-organisms, plants)</li> </ul>
Annex X (≥ 1000 t.p.a.)	<ul style="list-style-type: none"> <li>• Further <i>in vivo</i> mutagenicity studies (if + results)</li> <li>• Further reproductive toxicity studies               <ul style="list-style-type: none"> <li>• <i>Chronic toxicity (may)</i></li> <li>• <i>Carcinogenicity (may)</i></li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Further biotic degradation</li> <li>• Further fate</li> <li>• Long-term effects on terrestrial organisms</li> <li>• Long-term or reproductive toxicity to birds</li> </ul>



## Intelligent approach to property evaluation

- **New animal studies are a last resort** for REACH registration.
- **Data sharing** obligations for registrants of the same substance to avoid duplicate testing.
- Registrants must first **collect and assess all existing data**, then **identify data gaps** and consider whether **data waivers** apply or if gaps can be filled by **non-standard data** before deciding on new studies.
- **Data waivers:**
  - Impossible to conduct the study for technical reasons.
  - 'Low' exposure. i.e. '**Substance-tailored exposure-driven testing**' or chemical intermediates under 'strictly controlled conditions'.


## Non-standard Data for use in REACH

- **Annex XI 'adaptation'** of the standard information requirements.
- **Non-standard studies** or non-GLP.
- ***in vitro* studies.**
- Human **epidemiology** data.
- Information from structurally-related substances, i.e. **'read-across'** and **'chemical categories/grouping'**.
- Predictions from valid **(Q)SARs**
- **Weight of evidence** (WoE)

# Chemical Safety Assessment

- Substances at >10 tonnes per year have Chemical Safety Report (CSR) to record the Chemical Safety Assessment (CSA).
- Assessment if hazardous & if PBT/vPvB.
- 'Exposure scenario' (ES) key output of the CSA process, i.e. a description of manufactured/used as 'operational conditions' (OCs) linked to 'risk management measures' (RMMs).
- Determine 'derived no effect level' (DNELs) for human populations, i.e. level below which adverse effects should not occur, based on toxicity data set using 'assessment factors'.
- Determine 'predicted no effect concentration' (PNECs) for the environmental compartments.
- Exposure assessments are calculated from the ESs for the risk characterisation.
- CSR summarised as an extended Safety Data Sheet (SDS), i.e. essential element of supply chain communication to Downstream Users

# Evaluation Overview



MSCA = Member State Competent Authority

## Compliance Checks

- Compliance check (CCH) REACH allows ECHA to **verify that the information meets the data requirements**
- Although all registration dossiers must pass the Technical Completeness Check (TCC), there is no assessment of the quality or adequacy of the registration information
- CCHs on at least 5% of registration dossiers for each tonnage band
- 1,200 registration dossiers from 2010 deadline will be checked for compliance by end of 2013
- So far the majority has resulted in an ECHA decision requesting further information
- Quality of many of the registration dossiers can and needs to be improved

## Testing Proposal Examinations

- All **Testing Proposals** from registrants for higher-tier studies have to be evaluated
- Over 1,000 testing proposals from 2010 processed but many decisions still to be adopted
- Mostly authorising the testing as proposed or with modifications
- Third parties have only very rarely submitted scientifically valid information or studies making testing unnecessary

## Substance Evaluation

- New process under REACH to **clarify potential risk** not identified in the registration (i.e. to get extra hazard &/or exposure data)
- First **Community Rolling Action Plan** ('CoRAP') of **90 substances** as a 'rolling' 3-year list for 2012 to 2014
- Over 30 decisions to take and 46 new evaluations to be monitored from the 2012 list.
- ECHA compiles an annual proposal for CoRAP update by October for adoption by 31 March.
- Member States undertake the substance evaluation within 12 months

## ECHA's Strategic Aims

Four strategic aims developed to support prioritisation & guide how ECHA:

- approaches its activities
- allocates resources
- motivates its staff
- Getting better quality data from industry
- Using data intelligently for identifying and addressing chemicals of concern
- Becoming the regulatory science hub
- Using resources efficiently and effectively